/ Not yet recruitingNot Applicable Randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of a herbal combination product, Eviprostat N, in the treatment of moderate LUTS associated with benign prostatic hyperplasia” - EVE 2004/01
/ Not yet recruitingNot Applicable Randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of a herbal combination product, Eviprostat N, in the treatment of moderate LUTS associated with benign prostatic hyperplasia” - EVE 2004/01
100 Clinical Results associated with Pharmazeutische Fabrik Evers GmbH & Co. KG
0 Patents (Medical) associated with Pharmazeutische Fabrik Evers GmbH & Co. KG
On 10.05.2023 the Austrian Federal Competition Authority was notified of the following merger: Dermapharm Holding SE (Germany) intends to (indirectly) acquire 53.5% of the shares (with an option to increase them up to 61%) in and sole control over Pharmazeutische Fabrik Montavit Ges.m.b.H (Austria). The following Austrian NACE codes are concerned: Manufacture of pharmaceutical products and Wholesale of pharmaceutical goods. Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 07.06.2023. Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date. Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position. The Federal Competition Authority and the Federal Cartel Prosecutor have waived their right to apply for examination of the merger by the Cartel Court before the deadline. The standstill obligation (§ 17(1) Cartel Act) ends with effect from 30.05.2023.
100 Deals associated with Pharmazeutische Fabrik Evers GmbH & Co. KG
100 Translational Medicine associated with Pharmazeutische Fabrik Evers GmbH & Co. KG